Horizon Discovery Strengthens Board
News Jun 09, 2014
Dr. Susan Galbraith, Senior Vice President and Head of Oncology Innovative Medicines at AstraZeneca, and Susan Searle, co-founder and ex-CEO of Imperial Innovations Group plc, have been appointed as non-executive directors on the company’s board.
Dr. Susan Galbraith trained as a clinical oncologist, after studying medicine at Manchester and Cambridge Universities, and joins with over 20 years’ combined academic and industry experience. Susan was previously at Bristol-Myers Squibb, where she was Vice President of Oncology and Clinical Biomarkers from 2008 to 2010. In her roles at both Bristol-Myers Squibb and AstraZeneca, Susan has successfully developed and delivered strategies for the oncology and biomarker groups, resulting in increased success rates, enhanced scientific reputation and high value collaborations. She has also delivered major reorganisations, redesigned governance processes, and contributed to discussions on drug and diagnostic development with regulatory agencies in North America and Europe.
Susan Searle has over 20 years’ commercial experience as an entrepreneur and innovator. She co-founded Imperial Innovations Group plc, now one of the world’s leading technology venture investment businesses, leading as CEO from 2002 to 2013. During this time the company invested over £120m which included several bioscience companies: Abingdon Health, Circassia, CellMedica, Psioxus and Respivert. Susan has held non-executive director positions for a range of technology, engineering and healthcare companies. Susan also sits on the advisory board for the Technology Strategy Board’s Emerging Technologies group, which defines and advises on emerging areas of technology; is a non-executive director and chair of the remuneration committee for Benchmark Holdings plc, an AIM listed agricultural biotechnology business; sits on the board and audit, risk and nominations committee of the QinetiQ Group plc, an engineering and technology services FTSE 250 company; and is a trustee of Fight for Sight, a charity that funds eye research.
Dr. Darrin Disley, Chief Executive Officer of Horizon Discovery Group, commented: “We are delighted that both Susan Galbraith and Susan Searle have agreed to join Horizon’s Board of Directors. Both have established highly successful careers in their chosen fields and also have proven leadership and advisory success. We believe each will be an invaluable asset to Horizon, and look forward to benefitting from their counsel.”
Dr. Susan Galbraith said: “Horizon Discovery is a leading light in the UK biotech industry. I am excited to join the Board at this pivotal time in the Company’s development.”
Susan Searle added: “Horizon is an excellent company with a great track-record of success and a differentiated technology platform. I am pleased to be joining the Board of Directors, and look forward to working with the team during this next stage of the Company’s growth.”
Dr. Ian Gilham, Chairman of Horizon’s Board of Directors, commented: “I would like to welcome Susan and Susan to the Board of Horizon and am delighted that two such outstanding and distinguished business leaders are joining us to help guide the next stage of the growth of the company.”
In a new study in cells, University of Illinois researchers have adapted CRISPR gene-editing technology to cause the cell’s internal machinery to skip over a small portion of a gene when transcribing it into a template for protein building. This gives researchers a way not only to eliminate a mutated gene sequence, but to influence how the gene is expressed and regulated.
Researchers published today a detailed description of the complete genome of bread wheat, the world's most widely-cultivated crop. This work will pave the way for the production of wheat varieties better adapted to climate challenges, with higher yields, enhanced nutritional quality and improved sustainability.